Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coadministration of inactivated COVID-19 vaccine with 23-valent pneumococcal polysaccharide vaccine and quadrivalent influenza vaccine
ChiCTR2100054674Phase 4Recruiting
- Sponsor
- Hubei Center for Disease Control and Prevention
- Start
- May 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of turkovac, 23-valent pneumococcal polysaccharide vaccine and quadrivalent influenza vaccine in coronavirus disease 2019 (COVID-19), pneumococcal disease and influenza (3 arms), sponsored by Hubei Center for Disease Control and Prevention. Primary endpoints: Positive conversion rate and antibody level, Adverse events within 30 minutes after each dose and 2 more. Started May 2021; status: recruiting.
02
Drugs
turkovac23-valent pneumococcal polysaccharide vaccinequadrivalent influenza vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)pneumococcal diseaseinfluenza
Beyond the preview
Go deeper on ChiCTR2100054674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054674.